EA201170053A1 - Способ получения и сушки твердого разагилина в форме основания - Google Patents

Способ получения и сушки твердого разагилина в форме основания

Info

Publication number
EA201170053A1
EA201170053A1 EA201170053A EA201170053A EA201170053A1 EA 201170053 A1 EA201170053 A1 EA 201170053A1 EA 201170053 A EA201170053 A EA 201170053A EA 201170053 A EA201170053 A EA 201170053A EA 201170053 A1 EA201170053 A1 EA 201170053A1
Authority
EA
Eurasian Patent Office
Prior art keywords
radugline
drying
obtaining
basis
solid
Prior art date
Application number
EA201170053A
Other languages
English (en)
Other versions
EA021472B1 (ru
Inventor
Антон Френкел
Ронен Бен-Давид
Original Assignee
Тева Фармасьютикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз, Лтд. filed Critical Тева Фармасьютикал Индастриз, Лтд.
Publication of EA201170053A1 publication Critical patent/EA201170053A1/ru
Publication of EA021472B1 publication Critical patent/EA021472B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

Описан кристаллический R(+)-N-пропаргил-1-аминоиндан, содержащий воду в количестве менее 0,5 мас.% и фармацевтическая композиция, содержащая его, и его способ получения и подтверждения. Также описан способ получения твердого разагилина в форме основания.
EA201170053A 2008-06-19 2009-06-19 Способ получения и сушки твердого разагилина в форме основания EA021472B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13248708P 2008-06-19 2008-06-19
PCT/US2009/003670 WO2009154777A2 (en) 2008-06-19 2009-06-19 Process for preparing and drying solid rasagiline base

Publications (2)

Publication Number Publication Date
EA201170053A1 true EA201170053A1 (ru) 2011-08-30
EA021472B1 EA021472B1 (ru) 2015-06-30

Family

ID=41431882

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170053A EA021472B1 (ru) 2008-06-19 2009-06-19 Способ получения и сушки твердого разагилина в форме основания

Country Status (13)

Country Link
US (2) US7968749B2 (ru)
EP (1) EP2299992A4 (ru)
JP (1) JP2011524907A (ru)
CN (1) CN102065853A (ru)
AU (1) AU2009260728B2 (ru)
BR (1) BRPI0909997A2 (ru)
CA (1) CA2727017A1 (ru)
EA (1) EA021472B1 (ru)
IL (1) IL209134A0 (ru)
MX (1) MX2010013875A (ru)
NZ (1) NZ589547A (ru)
WO (1) WO2009154777A2 (ru)
ZA (1) ZA201008755B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
DK2101569T3 (da) * 2006-12-14 2012-01-30 Teva Pharma Krystallinsk fast rasagilinbase
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
MX2010007601A (es) * 2008-01-11 2010-08-03 Teva Pharma Formulaciones de rasagilina, su preparacion y uso.
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
CN103893160A (zh) * 2008-06-13 2014-07-02 泰华制药工业有限公司 雷沙吉兰用于改善帕金森氏症
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
KR20120137373A (ko) * 2010-04-30 2012-12-20 테이코쿠 팔마 유에스에이, 인코포레이티드 프로필아미노인단 경피 조성물
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
CA2851276A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
WO2013139387A1 (en) 2012-03-21 2013-09-26 Synthon Bv Stabilized pharmaceutical compositions comprising rasagiline salts
CA2882072A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulations of rasagiline
EP2891647B1 (en) * 2012-08-31 2020-08-26 Sumitomo Chemical Company, Limited Method for producing (r)-1,1,3-trimethyl-4-aminoindane
CN104797245B (zh) 2012-11-02 2018-05-04 帝国制药美国公司 丙炔基氨基茚满透皮组合物
US9151660B2 (en) * 2013-05-22 2015-10-06 Professional Compounding Centers Of America (Pcca) Method for validation of pharmaceutical formulation composition weight

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA2275425C (en) * 1996-12-18 2009-08-04 Michael Chorev Aminoindan derivatives
AU2003290838A1 (en) * 2002-11-15 2004-06-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
MX2007010233A (es) * 2005-02-23 2007-11-07 Teva Pharma Formulaciones de rasagilina de uniformidad de contenido mejorada.
AU2006316585B2 (en) * 2005-11-17 2012-09-20 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
JP4989153B2 (ja) * 2006-08-15 2012-08-01 コスモ石油株式会社 ５−アミノレブリン酸リン酸塩の新規結晶及びその製造方法
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EP2101570B1 (en) * 2006-12-14 2013-02-13 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
DK2101569T3 (da) * 2006-12-14 2012-01-30 Teva Pharma Krystallinsk fast rasagilinbase
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
KR101523195B1 (ko) 2007-12-24 2015-05-27 시플라 리미티드 프로파길화된 아미노인단 유도체의 합성방법
MX2010007601A (es) * 2008-01-11 2010-08-03 Teva Pharma Formulaciones de rasagilina, su preparacion y uso.
EP2271612B1 (en) 2008-03-31 2016-08-10 Actavis Group PTC EHF Rasagiline mesylate particles and process for the preparation thereof
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
CN103893160A (zh) * 2008-06-13 2014-07-02 泰华制药工业有限公司 雷沙吉兰用于改善帕金森氏症
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
CN101606923B (zh) 2008-06-20 2013-01-09 重庆医药工业研究院有限责任公司 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
WO2011012140A2 (en) * 2008-07-11 2011-02-03 Synthon Bv Polymorphs of rasagiline hydrochloride
US20100041920A1 (en) 2008-07-18 2010-02-18 Stephen Benedict David Winter New salt forms of an aminoindan derivative
US20100029987A1 (en) * 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
US20110263719A1 (en) 2008-07-30 2011-10-27 Vinayak Gore Polymorphic form of rasagiline mesylate
EP2181980A1 (en) 2008-10-28 2010-05-05 Chemo Ibérica, S.A. A process for the preparation of (R)-1-aminoindanes
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
EP2456750A2 (en) 2009-07-20 2012-05-30 Medichem, S.A. New form of the aminoindan mesylate derivative rasaginline mesylate
AU2010274589A1 (en) 2009-07-23 2012-02-16 Alkem Laboratories Ltd. Oral pharmaceutical composition of rasagiline and process for preparing thereof
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan

Also Published As

Publication number Publication date
WO2009154777A4 (en) 2010-07-01
CN102065853A (zh) 2011-05-18
EP2299992A4 (en) 2015-10-21
NZ589547A (en) 2013-03-28
AU2009260728A1 (en) 2009-12-23
WO2009154777A3 (en) 2010-05-06
JP2011524907A (ja) 2011-09-08
BRPI0909997A2 (pt) 2015-10-27
US20110281953A1 (en) 2011-11-17
EP2299992A2 (en) 2011-03-30
ZA201008755B (en) 2012-02-29
MX2010013875A (es) 2011-01-20
CA2727017A1 (en) 2009-12-23
AU2009260728B2 (en) 2015-01-29
EA021472B1 (ru) 2015-06-30
US20090318564A1 (en) 2009-12-24
WO2009154777A2 (en) 2009-12-23
WO2009154777A9 (en) 2011-01-27
US7968749B2 (en) 2011-06-28
IL209134A0 (en) 2011-01-31
US8163960B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
EA201170053A1 (ru) Способ получения и сушки твердого разагилина в форме основания
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
BRPI0512347A (pt) preparação da pregabalina e compostos relacionados
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EP2589392A3 (en) Process for stabilizing an adjuvant containing vaccine composition
ATE458535T1 (de) Verfahren zur herstellung von konzentrierten tensidzusammensetzungen
GEP20146114B (en) New crystalline form vi of agomelatine, preparation method and application thereof
IS8669A (is) Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í
GT200600346A (es) Nueva fórmula cristalina v de la agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen
EP2380850A4 (en) MODIFIED SODIUM MONTMORILLONITE, PREPARATION METHOD AND USE
JO3172B1 (ar) تركيبة وطريقة وتحضير الصفراء الصناعية
ECSP055859A (es) Forma cristalina alfa del renelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
NZ600263A (en) 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
EA201071167A1 (ru) Стабилизированные олеосомные композиции и способы их получения
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
IL205350A0 (en) Novel 1, 3- dihydro - 5 - isobenzofurancarbonitrile derivatives and pharmacetical composition thereof for the treatment of premature ejaculation
JP2010536929A5 (ru)
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
EA200900463A1 (ru) Арипипразола гемифумарат и способ его получения
EA200601651A1 (ru) Полиморфные формы трет-бутилового эфира аторвастатина и их использование в качестве промежуточных соединений для получения аторвастатина
WO2010023473A3 (en) Crystalline form of sunitinib and processes for its preparation
WO2009151770A3 (en) Colchicine solid-state forms; methods of making; and methods of use thereof
EA200701686A1 (ru) Свободное основание лерканидипина
DK1957463T3 (da) Fremgangsmåde til fremstilling af 5-fluor-1,3-dialkyl-1H-pyrazol-4-carboxylsyrechlorider
EA200700191A1 (ru) Композиции, содержащие никорандил, способ получения и применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU